Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment

被引：7
|
作者：
Thayer, David [1 ]
Noda, Christopher [1 ]
Charalel, Resmi [1 ]
Mills, Abigail [1 ]
Chang, Randy [2 ]
Tao, Yu [3 ]
Akinwande, Olaguoke [1 ,4 ]
机构：
[1] Washington Univ, Mallinckrodt Inst Radiol, Div Intervent Radiol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Div Intervent Radiol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Siteman Biostat, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 04期
关键词：
advanced hepatocellular carcinoma; comparative effectiveness; hazard ratio; liver cancer-specific survival; nonoperative treatment; overall survival; palliation; prognostic prediction; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; COHORT; MULTICENTER; SORAFENIB; RESECTION; THERAPY;
D O I：
10.2217/cer-2017-0064
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperative/interventional treatment (NOT). Materials & methods: A total of 12,520 HCC patients from the Surveillance, Epidemiology and End Results database were categorized by treatment with either radioembolization or NOT. Kaplan-Meier and multivariate Cox regression were conducted. Results: The TARE group had both a significantly longer median overall survival than the NOT group (TARE = 9 months; NOT = 2 months; p < 0.0001) and a significantly higher probability of liver cancer-specific survival (hazard ratio = 0.474). Conclusion: TARE appears to provide a significant survival advantage over the NOT population in advanced HCC patients.
引用
收藏
页码：343 / 356
页数：14
相关论文
共 50 条
  • [21] Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization
    Memon, Khairuddin
    Kulik, Laura M.
    Lewandowski, Robert J.
    Wang, Edward
    Wang, Jonathan
    Ryu, Robert K.
    Hickey, Ryan
    Vouche, Michael
    Baker, Talia
    Ganger, Daniel
    Gates, Vanessa L.
    Habib, Ali
    Mulcahy, Mary F.
    Salem, Riad
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2014, 25 (07) : 1056 - 1066
  • [22] Superselective transarterial radioembolization for the treatment of hepatocellular carcinoma
    Kim, Gyoung Min
    INTERNATIONAL JOURNAL OF GASTROINTESTINAL INTERVENTION, 2021, 10 (04): : 165 - 168
  • [23] Similar Transplant-Free Survival With Transarterial Chemoembolization (TACE) Versus Transarterial Radioembolization (TARE) in Patients With Hepatocellular Carcinoma
    Bhatt, Divya
    Patel, Amitkumar
    Achdjian, Stacy
    Ramanathan, Meera
    AL-Jashaami, Layth
    Choi, Myunghan
    Seetharam, Anil B.
    GASTROENTEROLOGY, 2016, 150 (04) : S1132 - S1133
  • [24] Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
    Labeur, Tim A.
    Berhane, Sarah
    Edeline, Julien
    Blanc, Jean-Frederic
    Bettinger, Dominik
    Meyer, Tim
    Van Vugt, Jeroen L. A.
    Ten Cate, David W. G.
    De Man, Robert A.
    Eskens, Ferry A. L. M.
    Cucchetti, Alessandro
    Bonnett, Laura J.
    Van Delden, Otto M.
    Klumpen, Heinz-Josef
    Takkenberg, R. Bart
    Johnson, Philip J.
    LIVER INTERNATIONAL, 2020, 40 (01) : 215 - 228
  • [25] IMPROVED SURVIVAL PREDICTION AND COMPARISON OF PROGNOSTIC MODELS FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB
    Labeur, Tim
    Berhane, Sarah
    Edeline, Julien
    Blanc, Jean-Frederic
    Bettinger, Dominik
    Meyer, Timothy
    van Vugt, Jeroen
    Ten Cate, David
    De Man, Robert A.
    Eskens, Ferry
    Cucchetti, Alessandro
    Van Delden, Otto
    Klumpen, Heinz-Josef
    Takkenberg, Robert Bart
    Johnson, Philip
    HEPATOLOGY, 2019, 70 : 525A - 526A
  • [26] RADIOEMBOLIZATION VERSUS TRANSARTERIAL CHEMOEMBOLIZATION BRIDGING TREATMENT PRIOR TO LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
    Raduenz, S.
    Treckmann, J.
    Theysohn, J. M.
    Mueller, S.
    Best, J.
    Paul, A.
    Benkoe, T.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 8 - 8
  • [27] Radioembolization Versus Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study
    Akinwande, Olaguoke
    Philips, Prejesh
    Scoggins, Charles
    Martin, Robert C. G.
    ANTICANCER RESEARCH, 2016, 36 (01) : 239 - 246
  • [28] Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality
    Kim, Do Young
    Han, Kwang-Hyub
    HEPATOLOGY INTERNATIONAL, 2016, 10 (06) : 883 - 892
  • [29] Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality
    Do Young Kim
    Kwang-Hyub Han
    Hepatology International, 2016, 10 : 883 - 892
  • [30] Sorafenib Associated Survival in Treatment Naive Versus Treatment Experienced Patients With Advanced Hepatocellular Carcinoma
    Devlin, Paulina
    Cheng, Shanna
    Vyas, Rahul
    Parikh, Neehar D.
    GASTROENTEROLOGY, 2016, 150 (04) : S516 - S516
12345